Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24667814 | 0.98 | GBA2 (0.39) | GBA2CES1CYP4F2CYP4A11 | |
| SCHEMBL20201547 | 0.95 | GBA2 (0.35) | GBA2CES1CYP4F2CYP4A11 | |
| SCHEMBL20201545 | 0.95 | GBA2 (0.35) | GBA2CES1CYP4F2CYP4A11 | |
| SCHEMBL19420786 | 0.95 | GBA2 (0.38) | GBA2CES1CYP4F2CYP4A11 | |
| SCHEMBL20314553 | 0.95 | GBA2 (0.33) | GBA2 | |
| SCHEMBL19420784 | 0.93 | GBA2 (0.37) | GBA2CES1CYP4F2CYP4A11 | |
| SCHEMBL19420766 | 0.93 | GBA2 (0.37) | GBA2CES1CYP4F2CYP4A11 | |
| SCHEMBL20314554 | 0.93 | GBA2 (0.33) | GBA2CYP4F2CYP4A11 | |
| SCHEMBL18591714 | 0.93 | GBA2 (0.33) | GBA2CYP4F2CYP4A11 | |
| SCHEMBL20314558 | 0.93 | GBA2 (0.33) | GBA2CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20210145832-A1 | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20180147202-A1 | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147202-A1 | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | TBK1, TBKBP1, TNKS | GBA2 3916/4885CES1 2763/4885CYP4F2 4782/4885 |
| US-20210145832-A1 | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | TBK1, TNKS, TBKBP1 | GBA2 3759/4885CES1 2557/4885CYP4F2 4806/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | GBA2 1999/4885CES1 3204/4885CYP4F2 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.